- Trials with a EudraCT protocol (255)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
255 result(s) found for: Prostate gland.
Displaying page 1 of 13.
EudraCT Number: 2012-001864-30 | Sponsor Protocol Number: MIP-1404-201 | Start Date*: 2012-09-25 | |||||||||||
Sponsor Name:Molecular Insight Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (E... | |||||||||||||
Medical condition: Prostate Cancer within prostate gland and metastatic prostate cancer in regional lymph nodes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) CZ (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021501-20 | Sponsor Protocol Number: 2010-021501-20 | Start Date*: 2010-06-22 | |||||||||||
Sponsor Name:ISTITUTO NEUROLOGICO MEDITERRANEO NEUROMED | |||||||||||||
Full Title: study for evaluation of 18F-choline PET/CT efficacy in patients with prostate carcinoma. | |||||||||||||
Medical condition: patient with prostate carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004406-93 | Sponsor Protocol Number: PDD-PC-01 | Start Date*: 2007-05-29 | |||||||||||
Sponsor Name:Klinikum der Universität München | |||||||||||||
Full Title: Photodynamische Diagnostik mit 5-Aminolävulinsäure zur Beurteilung der intraoperativen Absetzungsränder im Rahmen der radikalen Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom | |||||||||||||
Medical condition: Patients with prostate carinoma who will undergo radical prostatectomy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003495-11 | Sponsor Protocol Number: GOUP 01/2004 | Start Date*: 2005-03-16 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO | |||||||||||||
Full Title: PHASE III STUDY OF CHEMOHORMONAL THERAPY WITH TO DIFFERENT MODALITIES CONCOMITANT OR ALTERNATE VERSUS HORMONAL THERAPY ALONE IN ADVANCED PROSTATE CANCER PATIENTS. | |||||||||||||
Medical condition: ADVANCED PROSTATE CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000495-14 | Sponsor Protocol Number: D7913L00031 | Start Date*: 2005-03-14 | |||||||||||
Sponsor Name:ASTRAZENECA | |||||||||||||
Full Title: A PHASE II, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF ZD1839 (IRESSA?) IN COMBINATION WITH CASODEX? IN PATIENTS WITH OPERABLE PROSTATE CANCER | |||||||||||||
Medical condition: OPERABLE PROSTATE CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001361-81 | Sponsor Protocol Number: ICO-N-2016-01 | Start Date*: 2017-02-10 | |||||||||||
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000193-31 | Sponsor Protocol Number: PR08 | Start Date*: 2004-10-04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name: University College London | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Prostate Cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012809-19 | Sponsor Protocol Number: CLIN902 PCM203 | Start Date*: 2009-07-15 | |||||||||||
Sponsor Name:STEBA BIOTECH SA | |||||||||||||
Full Title: VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCER | |||||||||||||
Medical condition: Localized prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) NL (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000876-26 | Sponsor Protocol Number: CLIN801 PCM201 | Start Date*: 2008-05-02 | |||||||||||
Sponsor Name:STEBA BIOTECH NV | |||||||||||||
Full Title: "VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE" | |||||||||||||
Medical condition: The Treatment of prostate cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) GB (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021434-55 | Sponsor Protocol Number: FE 200486 CS35A | Start Date*: 2010-11-11 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring And... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: HU (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) BE (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001992-22 | Sponsor Protocol Number: ADVANCE | Start Date*: 2018-06-12 | ||||||||||||||||||||||||||
Sponsor Name:University of Oxford | ||||||||||||||||||||||||||||
Full Title: Phase II open label randomised safety and efficacy study of the viral vectored ChAd-MVA 5T4 vaccine in combination with PD-1 checkpoint blockade in low- or intermediate-risk localized or locally ad... | ||||||||||||||||||||||||||||
Medical condition: Low- and intermediate-risk prostate cancer and advanced metastatic prostate cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001530-40 | Sponsor Protocol Number: HEC WST06 1276N/WST 2.24 | Start Date*: 2006-07-18 | |||||||||||
Sponsor Name:STEBA FRANCE | |||||||||||||
Full Title: Vascular targeted photodynamic therapy using WST09 for patients with untreated localised prostate cancer - Repeat procedure – Phase IIa, Single centre, open-label study. | |||||||||||||
Medical condition: Localised Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006055-39 | Sponsor Protocol Number: FE200486 CS26 | Start Date*: 2008-01-30 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androge... | |||||||||||||
Medical condition: Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: HU (Completed) FI (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006913-34 | Sponsor Protocol Number: FE200486 CS21A | Start Date*: 2007-03-23 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation The... | |||||||||||||
Medical condition: Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: HU (Completed) NL (Completed) DE (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004943-72 | Sponsor Protocol Number: FE200486CS15A | Start Date*: 2006-07-17 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: An Open-Label, Multi-Centre, Extension Study, evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens, 240 mg (40 mg/mL), 240 mg (60 mg/mL), in Patients ... | |||||||||||||
Medical condition: Prostate cancer patient | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) FI (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012405-18 | Sponsor Protocol Number: 09/0221 | Start Date*: 2010-02-15 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Single site, phase II, double blind, randomised, placebo controlled study of the effect of dutasteride (Avodart)0.5 mg on the volume and characteristics of prostate cancer, as assessed by multifunc... | |||||||||||||
Medical condition: Low risk prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2004-003814-40 | Sponsor Protocol Number: FE200486 CS12A | Start Date*: 2005-02-01 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancer | |||||||||||||
Medical condition: Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004572-13 | Sponsor Protocol Number: ARD-0301-010 | Start Date*: 2006-11-06 | |||||||||||
Sponsor Name:Ardana Bioscience Ltd | |||||||||||||
Full Title: A Phase II multi-centre, randomized, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of two loading dose regimens of a new GnRH antagonist, Teverelix, lon... | |||||||||||||
Medical condition: Locally advanced and/or metatstatic prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005438-20 | Sponsor Protocol Number: ESTO1 | Start Date*: 2012-05-22 | |||||||||||
Sponsor Name:University of Tampere | |||||||||||||
Full Title: Effects of short-term atorvastatin treatment on prostate cancer - a pre-surgical pilot trial | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004774-17 | Sponsor Protocol Number: ESTO2 | Start Date*: 2018-08-23 | |||||||||||||||||||||||||||||||
Sponsor Name:Pirkanmaan sairaanhoitopiiri | |||||||||||||||||||||||||||||||||
Full Title: Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, doub... | |||||||||||||||||||||||||||||||||
Medical condition: Metastatic prostate cancer managed with androgen deprivation therapy | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||||||||||||
Trial protocol: FI (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
